Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight

Autor: Ebbie Chaluluka, Kephas Otieno, Kassoum Kayentao, Feiko O. ter Kuile, Sheick Oumar Coulibaly, Emmanuel Arinaitwe, Meghna Desai, Ya Ping Shi, Ryan E. Wiegand, Peter Ouma, Steve Meshnick, Don P. Mathanga, Kimberly E. Mace, Ogobara K. Doumbo, Jacek Skarbinski, Julie Gutman, Steve M. Taylor, Carole Khairallah, Dabira Edgar, Linda Kalilani, Mulakwa Kamuliwo, Veronica Ades, Pascal Magnussen
Přispěvatelé: Other departments
Rok vydání: 2015
Předmět:
Microbiology (medical)
Adult
medicine.medical_specialty
Sulfadoxine
medicine.medical_treatment
Birth weight
030231 tropical medicine
Plasmodium falciparum
Drug Resistance
Drug resistance
Article
03 medical and health sciences
Antimalarials
Young Adult
0302 clinical medicine
Drug Therapy
Pregnancy
Internal medicine
parasitic diseases
medicine
Humans
030212 general & internal medicine
Prospective Studies
Pregnancy Complications
Infectious

Africa South of the Sahara
Dihydropteroate Synthase
Intermittent preventive therapy
business.industry
Infant
Newborn

Infant
Low Birth Weight

medicine.disease
Sulfadoxine/pyrimethamine
Malaria
Low birth weight
Drug Combinations
Infectious Diseases
Pyrimethamine
Treatment Outcome
Amino Acid Substitution
Immunology
Female
Mutant Proteins
medicine.symptom
business
medicine.drug
Zdroj: Clinical infectious diseases, 62(3), 323-333. Oxford University Press
ISSN: 1537-6591
1058-4838
Popis: Background: Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucial. Methods: Between 2009 and 2013, both the efficacy of IPTp-SP at clearing existing peripheral malaria infections and the effectiveness of IPTp-SP at reducing low birth weight (LBW) were assessed among human immunodeficiency virus–uninfected participants in 8 sites in 6 countries. Sites were classified as high, medium, or low resistance after measuring parasite mutations conferring SP resistance. An individual-level prospective pooled analysis was conducted. Results: Among 1222 parasitemic pregnant women, overall polymerase chain reaction–uncorrected and –corrected failure rates by day 42 were 21.3% and 10.0%, respectively (39.7% and 21.1% in high-resistance areas; 4.9% and 1.1% in low-resistance areas). Median time to recurrence decreased with increasing prevalence of Pfdhps-K540E. Among 6099 women at delivery, IPTp-SP was associated with a 22% reduction in the risk of LBW (prevalence ratio [PR], 0.78; 95% confidence interval [CI], .69–.88; P < .001). This association was not modified by insecticide-treated net use or gravidity, and remained significant in areas with high SP resistance (PR, 0.81; 95% CI, .67–.97; P = .02). Conclusions: The efficacy of SP to clear peripheral parasites and prevent new infections during pregnancy is compromised in areas with >90% prevalence of Pfdhps-K540E. Nevertheless, in these high-resistance areas, IPTp-SP use remains associated with increases in birth weight and maternal hemoglobin. The effectiveness of IPTp in eastern and southern Africa is threatened by further increases in SP resistance and reinforces the need to evaluate alternative drugs and strategies for the control of malaria in pregnancy.
Databáze: OpenAIRE